Testosterone Treatment Lawsuits Move Forward, With Issuance of Protective Order in Federal Testosterone Litigation
New York, New York (PRWEB) September 05, 2014 -- The federal litigation involving the cardiovascular risks allegedly associated with prescription testosterone treatments (http://www.injurybeacon.com/testosterone-androgel/) continues to move forward in U.S. District Court, Northern District of Illinois, Bernstein Liebhard LLP reports. On September 1st, the Court issued a Stipulated Protective Order that governs the manner in which confidential information, including certain internal documents from pharmaceutical companies, as well as plaintiffs’ personal information, should be handled. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
“Our Firm continues to receive inquires from men who allegedly suffered serious heart complications due to the use of low testosterone therapy. We are pleased this proceeding is moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating testosterone lawsuits on behalf of men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other life-threatening heart problems due to their use of prescription testosterone medications.
Testosterone Litigation
Court documents indicate that more than 170 testosterone treatment lawsuits have been filed in the Northern District of Illinois against the manufacturers of AndroGel, Testim, Axiron and other prescription medications used to treat low testosterone levels in men. These claims accuse the defendants of failing to warn doctors and patients about their potential to cause life-threatening cardiovascular events, and of concealing those risks from the public.
According to court records, the testosterone litigation began to grow shortly after the U.S. Food & Drug Administration (FDA) announced in January that it was investigating the cardiovascular side effects potentially associated with this class of drugs. The agency is scheduled to convene an outside panel of advisors on September 17th to discuss this matter, and to explore ways in which such risks might be mitigated. Earlier this week, FDA reviewers released a report in advance of the meeting which concluded that there was little evidence to indicate that low testosterone therapy provided any benefits for men who used the drugs to alleviate fatigue, low libido and other symptoms associated with aging.*
Alleged victims of heart attacks, strokes or blood clots allegedly associated with testosterone replacement therapy may be entitled to file their own testosterone lawsuit. To learn more, please visit Bernstein Liebhard LLP’s website, or call the Firm today at 800-511-5092.
*http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/reproductivehealthdrugsadvisorycommittee/ucm412537.pdf, FDA, September 3, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
https://www.injurybeacon.com
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, InjuryBeacon.com, http://www.injurybeacon.com, +1 800-511-5092, [email protected]
Share this article